Clinical trials: Symptomatic Patients (Stenosis > 50%)
Patients With Aterosclerotic Carotid Stenosis, Symptomatic Patients (Stenosis > 50%)
The SIBERIA Trial (Acculink™ Versus CGuard™)
That the study will be carried out as it has the protocol instructions, respecting the applicable regulations for clinical investigations with medical devices and following the internationally accepted ethical standards
- Conditions
- Patients With Aterosclerotic Carotid Stenosis, Symptomatic Patients (Stenosis > 50%), Asymptomatic Patients (Stenosis ≥80%)
- Trial name
- CAS (NCT03488199)
- Testing
- Stent Acculink ™, CGuardTM™
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Patients With Aterosclerotic Carotid Stenosis, Symptomatic Patients (Stenosis > 50%)
Carotid Revascularization With MicroNet Covered Stent Comparing Early Neurological Outcomes With Distal Versus Proximal EPS
The SIBERIA study demonstrated a clear advantage of CGuard stent implantation over the existing classical stent when using a distal anti-embolic device.
- Conditions
- Patients With Aterosclerotic Carotid Stenosis, Symptomatic Patients (Stenosis > 50%), Asymptomatic Patients (Stenosis ≥80%)
- Trial name
- SIBERIA-2 (NCT05257161)
- Testing
- Emboshield NAV6™, Mo.Ma™
- Where
- Russia
- Volunteers
- 366 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation